Axon 2720
CAS [1448693-69-3]
MF C19H18N10OMW 402.41
A-92 inhibits the stress response of general control nonderepressible 2 kinase (GCN2 or EIF2AK4) (IC50 value of <0.3 μM). Possible chemotherapeutic drug for the treatment of cancer.
KEYWORDS: A-92 | supplier | GCN2 inhibitor | A92 | A 92 | CAS [1448693-69-3] | Unfolded Protein Response (EIF2 Selective) | GCN | Inhibitor | Enzymes | GCN2 | eIF2α | EIF2AK4 | General Control Nonderepressible 2 Kinase | tRNA
J Brazeau et al. Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2. ACS Med Chem Lett. 2014 Apr 10; 5(4): 282–283. |
3-(1H-Indazol-6-yl)-N-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine
[1448693-69-3]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。